Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements - Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...

Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...